Table 4.
Comparison of the clinical and pathological factors associated with the effect of TMTs
| Decreased (n=11) | Increased or stable (n=7) | P-value | |
|---|---|---|---|
| Age, years; median (range) | 59 (34–75) | 46 (33–62) | 0.10 |
| Sex, n (%) | 0.50 | ||
| Male | 9 (81.8) | 7 (100) | |
| Female | 2 (18.2) | 0 | |
| Tumor laterality, n (%) | 1.00 | ||
| Left | 2 (18.2) | 2 (28.6) | |
| Right | 9 (81.8) | 5 (71.4) | |
| ECOG performance status, n (%) | 0.26 | ||
| 0 | 1 (9.1) | 1 (14.3) | |
| 1 | 10 (90.9) | 4 (57.1) | |
| 2 | 0 | 2 (28.6) | |
| TMT, n (%) | 0.23 | ||
| Sorafenib | 4 (36.4) | 5 (71.4) | |
| Sunitinib | 4 (36.4) | 2 (28.6) | |
| Axitinib | 3 (27.3) | 0 | |
| Cycles of TMT, weeks; median (range) | 2.5 (1–3) | 1.5 (1–3) | 0.24 |
| Clinical stage, n (%) | 1.00 | ||
| T3b | 10 (90.9) | 7 (100) | |
| T3c | 1 (9.1) | 0 | |
| Nodal stage, n (%) | 0.14 | ||
| N0 | 9 (81.8) | 3 (42.9) | |
| N1 | 2 (18.2) | 4 (57.1) | |
| Metastatic disease, n (%) | 1 (9.1) | 1 (14.3) | 1.00 |
| Thrombus level, n (%) | 0.17 | ||
| I | 0 | 1 (14.3) | |
| II | 7 (63.6) | 5 (71.4) | |
| III | 3 (27.3) | 1 (14.3) | |
| IV | 1 (9.1) | 0 | |
| Histology, n (%) | 1.00 | ||
| ccRCC | 9 (81.8) | 6 (85.7) | |
| Papillary cell RCC | 1 (9.1) | 1 (14.3) | |
| Chromophobe RCC | 1 (9.1) | 0 | |
| Fuhrman grade, n (%) | 0.42 | ||
| 2 | 1 (11.1) | 2 (33.3) | |
| 3 | 6 (66.7) | 3 (50.0) | |
| 4 | 2 (22.2) | 1 (16.7) | |
| ASA score, n (%) | 0.51 | ||
| 1+2 | 8 (72.7) | 4 (57.1) | |
| 3+4 | 3 (27.3) | 3 (42.9) | |
| Hemoglobin, g/L; median (range) | 128 (68–141) | 117 (83–139) | 0.23 |
| Neutrophil count/mL; median (range) | 3.83 (1.00–6.31) | 4.88 (3.67–7.23) | 0.056 |
| NLR, median (range) | 2.36 (0.65–4.56) | 4.09 (1.51–6.60) | 0.28 |
| Albumin, g/L; median (range) | 39.45 (32–43.4) | 37.25 (30.7–60) | 0.17 |
| Creatinine, µmol/L; median (range) | 96.75 (55.9–146.9) | 95.55 (79.4–127.2) | 0.77 |
| LDH, U/L; median (range) | 184.15 (110.9–288.3) | 181.63 (156.1–530.6) | 0.63 |
| ALP, U/L; median (range) | 71.15 (64–126.1) | 73.23 (34.8–241.3) | 0.85 |
Abbreviations: ALP, alkaline phosphatase; ASA, American Society of Anesthesiologists; ccRCC, clear cell renal cell carcinoma; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; RCC, renal cell carcinoma; TMT, targeted molecular therapy; NLR, neutrophil to lymphocyte ratio.